A comprehensive view of Phase 3 Trial. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Eisai and Biogen disappointed by EMA's negative opinion on lecanemab for early Alzheimer's; the humanized anti-amyloid-beta monoclonal antibody was under review for mild cognitive impairment
Published: July 26, 2024 by Biogen Inc.
Merck receives positive EU CHMP opinion for KEYTRUDA and Padcev for first-line treatment of unresectable or metastatic urothelial carcinoma; based on Phase 3 KEYNOTE-A39 trial results
Published: July 26, 2024 by Merck & Co. Inc.
AbbVie gains European Commission approval for SKYRIZI® to treat moderate to severe ulcerative colitis in adults; supported by two pivotal Phase 3 trials showing clinical remission
Published: July 26, 2024 by AbbVie Inc.
European Commission approves Pfizer's DURVEQTIX® gene therapy for hemophilia B; reduces bleeds post-treatment with a median annualized bleed rate of zero bleeds after up to four years of follow-up
Published: July 25, 2024 by Pfizer Inc.
FDA Advisory Committee reviewed AstraZeneca’s Imfinzi for resectable lung cancer; AEGEAN Phase III trial shows 32% risk reduction in recurrence, progression, or death vs. chemotherapy alone
Published: July 25, 2024 by AstraZeneca AB

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count